Market Overview

The global clot management devices market share reached USD 1.90 billion in 2024 and is projected to grow to USD 2.90 billion by 2033, driven by rising thrombotic disorders, an aging population, and demand for minimally invasive thrombectomy solutions. Technological advances, favourable reimbursement and expanding specialist centres are accelerating adoption across hospitals and specialty clinics worldwide.

Study Assumption Years

• BASE YEAR: 2024.
• HISTORICAL YEAR: 2019–2024.
• FORECAST YEAR: 2025–2033.

Clot Management Devices Market — Key Takeaways

• Market size: USD 1.90 billion (2024); forecast USD 2.90 billion (2033); CAGR 4.58% (2025–2033).
• North America dominates (over 55.3% share in 2024), powered by advanced healthcare systems and reimbursement.
• Percutaneous thrombectomy devices are the largest product segment (~37.6% in 2024) due to rapid, minimally invasive clot removal.
• Hospitals are the primary end-user (~80.9% share), reflecting complex procedure capability and infrastructure.
• Growth is supported by expanding clinical trials, device approvals, and new product launches from major device manufacturers.

Market Growth Factors

1) Clinical burden, demographics & demand for minimally invasive care
The rising global rates of cardiovascular diseases, strokes, deep vein thrombosis (DVT), and pulmonary embolism (PE) are driving the demand for clot management devices. Factors like sedentary lifestyles, increasing obesity, high blood pressure, and a growing elderly population are heightening the risk of blood clots and putting more pressure on healthcare systems, which in turn boosts the need for quick and effective clot removal solutions. Minimally invasive thrombectomy procedures are a game changer—they shorten hospital stays, reduce complications, and help patients recover faster, which is a win for both hospitals and insurers. As more patients are diagnosed earlier and treatment approaches shift towards interventional methods, the demand for percutaneous thrombectomy systems and catheter-directed thrombolysis technologies is on the rise. These clinical and demographic trends are especially noticeable in developed healthcare systems, which often set the standard for adoption in other regions, leading to sustained growth and ongoing investment in clinical research.

2) Technological innovation and product differentiation
On the tech front, advancements like better aspiration and mechanical thrombectomy tools, enhanced catheter-directed thrombolysis systems, real-time imaging, AI-assisted diagnostics, and robotics are revolutionizing how these procedures are performed and boosting operator confidence. Innovations such as pressure-sensing aspiration algorithms, single-use large-bore aspiration tools, and computer-assisted vacuum thrombectomy (CAVT) have significantly improved clot capture rates and sped up procedures, making these interventional methods more appealing to healthcare providers. Manufacturers are setting themselves apart with algorithm-driven devices and integrated workflow features that cut down on procedure time and allow for treatment of a wider range of conditions, including pulmonary embolism and peripheral venous thrombus. These enhancements not only broaden the potential patient base but also encourage greater adoption in advanced medical centers, while ongoing product launches and regulatory approvals (like FDA and CE) keep refreshing hospital procurement cycles and shifting market shares among top suppliers.

3) Policy, reimbursement and commercialization dynamics
Favorable reimbursement frameworks and regulatory approvals play a crucial role in driving commercial success. In markets like the U.S., having supportive insurance coverage and clear reimbursement pathways for thrombectomy and thrombolysis procedures helps to eliminate financial hurdles for both hospitals and patients, which in turn speeds up adoption. Achieving regulatory milestones, such as FDA 510(k) clearances and approvals, not only validates new device classes but also opens the door for more clinicians to access these innovations and for hospitals to make purchases. At the same time, rising healthcare spending, government backing for advanced medical technologies, and the growth of specialized stroke and vascular centers are all contributing to an increase in treatment capacity. Additionally, strategic partnerships, mergers and acquisitions, and active clinical trial programs are all helping to accelerate commercialization and market entry. Together, these trends in policy, payer dynamics, and commercialization create a stable environment for manufacturers, allowing them to scale production, invest in post-market studies, and expand into new regions—ultimately supporting sustained growth in the clot management devices market.

Request for a sample copy of this report: https://www.imarcgroup.com/clot-management-devices-market/requestsample

Market Segmentation

By Product Type

• Neurovascular Embolectomy Devices — Devices designed to retrieve emboli from cerebral vasculature for stroke treatment; used in specialized neurointerventional procedures.
• Embolectomy Balloon Catheters — Catheters with inflatable balloons used to displace or extract clots during embolectomy procedures across vascular territories.
• Percutaneous Thrombectomy Devices — Minimally invasive systems for clot removal via percutaneous access; main category including mechanical and aspiration methods.
• Mechanical Thrombectomy — Devices that mechanically engage and remove thrombus using specialized retrieval or fragmentation mechanisms.
• Aspiration Thrombectomy — Suction-based systems designed to aspirate thrombus directly from vessels, improving speed and clot retrieval efficiency.
• Percutaneous Mechanical Thrombectomy (PMT) — Combination mechanical systems deployed percutaneously to fragment and extract thrombus using adjunctive tools.
• Catheter-Directed Thrombolysis Devices — Catheter systems that deliver thrombolytic drugs directly into clot, enabling focused dissolution with lower systemic exposure.
• Inferior Vena Cava Filters — Devices implanted in the inferior vena cava to prevent pulmonary embolism by trapping emboli.
• Permanent — IVC filters intended for long-term implantation without planned removal.
• Retrievable — IVC filters designed for temporary protection with the option for later retrieval.

By End-User

• Hospitals — Acute-care and tertiary hospitals providing comprehensive interventional, surgical, and post-procedural care for thrombotic conditions.
• Diagnostic Centers and Specialty Clinics — Outpatient centers and specialty clinics offering imaging, diagnostics and select interventional procedures for clot management.
• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Regional Insights

North America is set to dominate the clot management devices market, holding more than 55.3% of the share in 2024. This leadership is fueled by a high prevalence of thrombotic diseases, a robust clinical infrastructure, a strong presence of manufacturers, favorable reimbursement policies, and the swift adoption of minimally invasive thrombectomy technologies—particularly in the United States, which drives most of the regional demand.

Recent Developments & News

In recent months, there’s been a flurry of product launches and regulatory advancements: Argon Medical introduced the CLEANER Vac thrombectomy system in September 2024 and kicked off the CLEAN-PE trial in January 2025 to tackle pulmonary embolism. Meanwhile, Penumbra has made strides in arterial thrombectomy technology with the Lightning Bolt 7, which received FDA approval in March 2023, and has rolled out new iterations like Lightning Flash and Lightning Flash 2.0, featuring CAVT capabilities. Looking ahead to 2024 and 2025, we can expect FDA 510(k) clearances for innovative pulmonary artery devices and the completion of new thrombectomy system clinical trials and patents, highlighting a wave of rapid innovation, stronger evidence generation, and broader clinical adoption in specialized centers.

Key Players

• AngioDynamics Inc.
• Argon Medical Devices Inc.
• Boston Scientific Corporation
• DePuy Synthes Inc.
• Edwards Lifesciences Corporation
• iVascular S.L.U.
• Lemaitre Vascular Inc.
• Medtronic Inc.
• Straub Medical AG
• Stryker Corporation
• Teleflex Incorporated
• Vascular Solutions.

Ask Analyst for Customization:  https://www.imarcgroup.com/request?type=report&id=2131&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No: (+1-201971-6302)